Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Map To FDA RiskMAPs

This article was originally published in RPM Report

Executive Summary

Increased public scrutiny of drug safety is making risk management plans de rigeur for many new chemical entities and marketed products with definable adverse effects. FDA is using a system of special review teams to determine which plans pass muster.

You may also be interested in...



FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate

The message from RPM's FDA/CMS Summit Conference: if you want to handicap the effect of the continuing drug safety debate around FDA, you can track the progress of the Kennedy-Enzi bill through Congress - and listen to the tone of the comments from the agency's top managers and its critics. Both will tell you what's at stake for pharma in 2007.

Time to Pay the Piper? Industry Prepares for a Fight Over User Fees

The pharmaceutical industry and FDA are getting ready for a fight-and for once they are on the same side. They want Congress to reauthorize the Prescription Drug User Fee Act quickly and cleanly-without tacking on other reforms to FDA's drug regulations. They probably won't get their wish.

Time to Pay the Piper? Industry Prepares for a Fight Over User Fees

The pharmaceutical industry and FDA are getting ready for a fight-and for once they are on the same side. They want Congress to reauthorize the Prescription Drug User Fee Act quickly and cleanly-without tacking on other reforms to FDA's drug regulations. They probably won't get their wish.

Related Content

Topics

UsernamePublicRestriction

Register

PS080071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel